Science Explorer Back to mapMap
Discussion
Institution · Acadia Pharmaceuticals (United States)

Most cited papers from Acadia Pharmaceuticals (United States)

Acadia Pharmaceuticals (United States)

What are the most cited papers from Acadia Pharmaceuticals (United States)?

The most cited paper from Acadia Pharmaceuticals (United States) is "BART: Bayesian Additive Regression Trees" (Hugh Chipman, Edward I. George, Robert E. McCulloch, 2006), with 969 citations. Next come "Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial" (955) and "A new glucagon and GLP-1 co-agonist eliminates obesity in rodents" (645).

Showing 50 of 60 papers. Every paper with more than 59 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 BART: Bayesian Additive Regression Trees Hugh Chipman, Edward I. George, Robert E. McCulloch · ScholarlyCommons (University of Pennsylvania) Open access 2006 969
2 Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial Jeffrey L. Cummings, Stuart Isaacson, Roger Mills et al. · The Lancet 31 Oct 2013 955
3 A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Jonathan W. Day et al. · Nature Chemical Biology Open access 13 Jul 2009 645
4 A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents Brian Finan et al. · Nature Medicine Open access 8 Dec 2014 643
5 Control of cell cycle progression by c-Jun is p53 dependent Martin J. Schreiber, Andrea Kolbus, Fabrice Piu et al. · Genes & Development Open access Mar 1999 583
6 On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis Uli Hacksell, Ethan S. Burstein, Krista McFarland et al. · Neurochemical Research Open access 29 Mar 2014 298
7 Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis Herbert Y. Meltzer, Roger Mills, Stephen Revell et al. · Neuropsychopharmacology Open access 11 Nov 2009 297
8 The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine David M. Weiner, Herbert Y. Meltzer, Isaac Veinbergs et al. · Psychopharmacology 15 Jul 2004 254
9 Novel Selective Allosteric Activator of the M1Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats Carrie K. Jones, Ashley E. Brady, Albert A. Davis et al. · Journal of Neuroscience Open access 8 Oct 2008 245
10 Getting better and staying better: Assessing civility, incivility, distress, and job attitudes one year after a civility intervention. Michael P. Leiter, Arla Day, Debra Gilin Oore et al. · Journal of Occupational Health Psychology Open access Oct 2012 219
11 Cholecystokinin in the Rostral Ventromedial Medulla Mediates Opioid-Induced Hyperalgesia and Antinociceptive Tolerance Jennifer Yanhua Xie, David S. Herman, Carl‐Olav Stiller et al. · Journal of Neuroscience Open access 12 Jan 2005 206
12 Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist Kimberly E. Vanover et al. · Journal of Pharmacology and Experimental Therapeutics Open access 10 Feb 2006 203
13 5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics David M. Weiner, Ethan S. Burstein, N. T. Nash et al. · Journal of Pharmacology and Experimental Therapeutics Oct 2001 203
14 Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study Jeffrey Lorenz Neul, Alan K. Percy, Tim A. Benke et al. · Nature Medicine Open access Jun 2023 200
15 Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study Clive G. Ballard et al. · The Lancet Neurology 13 Feb 2018 190
16 Discovery of an Ectopic Activation Site on the M1Muscarinic Receptor Tracy A. Spalding, Carol Trotter, Niels Skjærbæk et al. · Molecular Pharmacology Jun 2002 187
17 Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist Ethan S. Burstein, Jin Ma, Steven Wong et al. · Journal of Pharmacology and Experimental Therapeutics Open access 16 Nov 2005 184
18 Evidence for a Model of Agonist-induced Activation of 5-Hydroxytryptamine 2A Serotonin Receptors That Involves the Disruption of a Strong Ionic Interaction between Helices 3 and 6 David A. Shapiro, Kurt Kristiansen, David M. Weiner et al. · Journal of Biological Chemistry Open access Mar 2002 172
19 RNA Editing Induces Variation in Desensitization and Trafficking of 5-Hydroxytryptamine 2c Receptor Isoforms Sébastien Marion, David M. Weiner, Marc G. Caron · Journal of Biological Chemistry Open access 2004 162
20 Trial of Pimavanserin in Dementia-Related Psychosis Pierre N. Tariot, Jeffrey L. Cummings, Maria Soto‐Martin et al. · New England Journal of Medicine Open access 21 Jul 2021 141
21 Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents Jonathan W. Day, Vasily M. Gelfanov, David L. Smiley et al. · Biopolymers 2012 135
22 Quantum key distribution with 1.25 Gbps clock synchronization Joshua C. Bienfang, Andrew J. Gross, Alan Mink et al. · Optics Express Open access 2004 128
23 The Second Intracellular Loop of the m5 Muscarinic Receptor Is the Switch Which Enables G-protein Coupling Ethan S. Burstein, Tracy A. Spalding, Mark R. Brann · Journal of Biological Chemistry Open access Sep 1998 125
24 Low Dose Bexarotene Treatment Rescues Dopamine Neurons and Restores Behavioral Function in Models of Parkinson’s Disease Krista McFarland, Tracy A. Spalding, David T. Hubbard et al. · ACS Chemical Neuroscience Open access 11 Oct 2013 122
25 Perceptual tuning and conscious attention: Systems of input regulation in visual information processing Thomas H. Carr, Verne R. Bacharach · Cognition 1976 122
26 Ties That Bond: Youth Sport as a Vehicle for Social Identity and Positive Youth Development Mark W. Bruner, Shea M. Balish, Christopher K Forrest et al. · Research Quarterly for Exercise and Sport 31 Mar 2017 120
27 Factor analytic support for social cognition as a separable cognitive domain in schizophrenia Daniel N. Allen, Gregory P. Strauss, Brad C. Donohue et al. · Schizophrenia Research 11 May 2007 115
28 RNA Editing of the Human Serotonin 5-HT2CReceptor Alters Receptor-mediated Activation of G13Protein Raymond D. Price, David M. Weiner, Mike S. S. Chang et al. · Journal of Biological Chemistry Open access Nov 2001 109
29 Pharmacology of N-desmethylclozapine☆ Jelveh Lameh, Ethan S. Burstein, Eric B. Taylor et al. · Pharmacology & Therapeutics 25 May 2007 104
30 Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor Petrine Wellendorph, Matilda W. Goodman, Ethan S. Burstein et al. · Neuropharmacology Jun 2002 104
31 Regional Stem Taper Equations for Eleven Conifer Species in the Acadian Region of North America: Development and Assessment Rongxia Li, Aaron R. Weiskittel, Adam R. Dick et al. · Northern Journal of Applied Forestry Mar 2012 101
32 Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed Ritsuko Sawada-Hirai, Ivy Jiang, Fei Wang et al. · Journal of Immune Based Therapies and Vaccines Open access 12 May 2004 98
33 Allosteric modulation of G-protein coupled receptors Anders A. Jensen, Tracy A. Spalding · European Journal of Pharmaceutical Sciences 31 Jan 2004 98
34 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day Herbert Y. Meltzer, Hélio Elkis, Kimberly E. Vanover et al. · Schizophrenia Research Open access 4 Sep 2012 95
35 Identification of a Ligand-dependent Switch within a Muscarinic Receptor Tracy A. Spalding, Ethan S. Burstein, Shaw C. Henderson et al. · Journal of Biological Chemistry Open access Aug 1998 93
36 The Reinforcing Properties of Alcohol are Mediated by GABAA1 Receptors in the Ventral Pallidum Harry L. June, Katrina L. Foster, Peter F. McKay et al. · Neuropsychopharmacology 20 May 2003 91
37 Very early activation of m-calpain in peripheral nerve during Wallerian degeneration Jonathan D. Glass, Deborah G. Culver, Allan I. Levey et al. · Journal of the Neurological Sciences Apr 2002 88
38 Novel retinoid-related molecules as apoptosis inducers and effectve inhibitors of human lung cancer cells in vivo Xianping Lu, Andrea N. Fanjul, Nathalie Picard et al. · Nature Medicine Jun 1997 87
39 Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis Tiffini Voss, Daun Bahr, Jeffrey L. Cummings et al. · Parkinsonism & Related Disorders Dec 2012 87
40 Pimavanserin: Potential Treatment For Dementia-Related Psychosis Jeffrey Cummings, Clive G. Ballard, Pierre N. Tariot et al. · The Journal of Prevention of Alzheimer s Disease Open access Oct 2018 86
41 Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation Tracy A. Spalding, Jian‐Nong Ma, Thomas J. Ott et al. · Molecular Pharmacology 8 Sep 2006 84
42 PharmVar GeneFocus: CYP2C9 Katrin Sangkuhl, Karla Claudio‐Campos, Larisa H. Cavallari et al. · Clinical Pharmacology & Therapeutics Open access 10 Jun 2021 80
43 Association of the human kainate receptor GluR7 gene (GRIK3) with recurrent major depressive disorder Hans H. Schiffer, Steve Heinemann · American Journal of Medical Genetics Part B Neuropsychiatric Genetics Open access 6 Sep 2006 79
44 Characterization of the Mas‐related gene family: structural and functional conservation of human and rhesus MrgX receptors Ethan S. Burstein, Thomas J. Ott, Michele Feddock et al. · British Journal of Pharmacology Open access 14 Nov 2005 79
45 Pharmacological profiles of opioid ligands at Kappa opioid receptors Parham Gharagozlou, Ezzat Hashemi, Timothy M. DeLorey et al. · BMC Pharmacology Open access 25 Jan 2006 77
46 A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model Kim E. Vanover, Adrienne J. Betz, Stephen G. Weber et al. · Pharmacology Biochemistry and Behavior Open access 21 Apr 2008 76
47 Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease Krista McFarland, Diana L. Price, Douglas W. Bonhaus · Behavioural Pharmacology Oct 2011 70
48 Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome Jeffrey Lorenz Neul, Alan K. Percy, Tim A. Benke et al. · Contemporary Clinical Trials Open access 8 Feb 2022 69
49 Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe Dragana Bugarski-Kirola, Celso Arango, Maurizio Fava et al. · The Lancet Psychiatry 30 Nov 2021 68
50 Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials Jennifer G. Goldman, Leah K. Forsberg, Bradley F. Boeve et al. · Alzheimer s Research & Therapy Open access 29 Oct 2020 68

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.